Hippocratic AI, the first Large Language Model (LLM) designed specifically for healthcare, announced its Founding Partner Program with 10 health systems and digital health companies.
Partners will help ensure the safety of Hippocratic AI’s LLM over the course of their five-year partnerships; they will guide the development of the model, participate in data governance and model safety committees, establish use cases, engage their medical professionals in conducting RLHF, and validate clinical and patient safety.
In addition, some partners have also chosen to invest in Hippocratic AI, bringing the company’s total funding to-date to $65 million. As shareholders, they will have additional oversight of the model.As shareholders, they will have additional oversight of the model.
Ravulizumab (Ultomiris), a terminal complement C5 inhibitor, did not improve functional status and survival in patients with amyotrophic lateral sclerosis (ALS), the phase III CHAMPION-ALS
Hippocratic AI Launches Founding Partner Program
by Fred Pennic Leave a Comment
What You Should Know:
Partners include:
Ravulizumab Showed Preclinical Promise for ALS. What Happened?
Ravulizumab (Ultomiris), a terminal complement C5 inhibitor, did not improve functional status and survival in patients with amyotrophic lateral sclerosis (ALS), the phase III CHAMPION-ALS
CHAI Releases Draft Responsible Health AI Framework
What You Should Know: – Today the Coalition for Health AI (CHAI) released a draft framework for responsible health AI with an invitation for public
Biotest increases revenues in the first 9 months by 4.5% to Euro 523 million – Biotech Investments
EQS-News: Biotest AG / Key word(s): 9 Month figures Biotest increases revenues in the first 9 months by 4.5% to Euro 523 million 14.11.2024 /